Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18950082 | 0.98 | EPHX1 (0.52) | HDAC1HDAC2HDAC3HDAC8EPHX1 | |
| SCHEMBL11639864 | 0.98 | EPHX1 (0.52) | HDAC1HDAC2HDAC3HDAC8EPHX1 | |
| SCHEMBL4072926 | 0.83 | EPHX1 (0.56) | HDAC1HDAC2HDAC3HDAC8EPHX1 | |
| SCHEMBL3891234 | 0.82 | — | — | |
| SCHEMBL1442907 | 0.81 | HDAC3 (0.49) | HDAC1HDAC2HDAC3HDAC8EPHX1 | |
| SCHEMBL16266153 | 0.80 | MAPT (0.62) | HDAC1HDAC2HDAC3HDAC8EPHX1 | |
| SCHEMBL253169 | 0.79 | HDAC1 (0.47) | HDAC1HDAC2HDAC3HDAC8EPHX1 | |
| SCHEMBL9229464 | 0.79 | HDAC1 (0.47) | HDAC1HDAC2HDAC3HDAC8EPHX1 | |
| SCHEMBL2420545 | 0.79 | EPHX1 (0.52) | HDAC1HDAC2HDAC3HDAC8EPHX1 | |
| SCHEMBL13731861 | 0.79 | EPHX1 (0.52) | HDAC1HDAC2HDAC3HDAC8EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017129818-A1 | LINKER MOLECULE AND USE THEREOF IN METHODS FOR PURIFYING PEPTIDES | HUMBOLDT-UNIVERSITÄT ZU BERLIN (DE) | 2017-08-03 | — | — | WO | disclosed |
| US-20110294813-A1 | OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | SHIONOGI & CO., LTD. (JP) | 2011-12-01 | — | — | US | disclosed |
| US-6346543-B1 | ADMINISTERING BACCATIN DERIVATIVE AS ANTICARCINOGENIC AGENT | AVENTIS PHARMA S.A. (FR) | 2002-02-12 | — | — | US | disclosed |
| US-5814658-A | Taxoids, their preparation and pharmaceutical compositions containing them | RHONE-POULENC RORER S.A. (FR) | 1998-09-29 | — | — | US | disclosed |
| US-5606068-A | Acid anhydrides, their preparation and their use | RHONE-POULENC RORER S.A. (FR) | 1997-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294813-A1 | OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD17B3, HSD17B1, HSD3B1 | HDAC1 179/4885HDAC2 329/4885HDAC3 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.